Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Diabetes / Metabolic Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting Phase III NCT03844048

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial — Active Not Recruiting • Phase III • Oncology • NCT03844048.

📅 13 May 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Phase III
NCT ID
NCT03844048
Start
2019-09-06
Completion
2027-08
ClinicaliQ Trial Snapshot
  • An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial — Active Not Recruiting • Phase III • Oncology • NCT03844048.
  • Venetoclax extension study collecting long-term safety data in patients continuing to benefit from treatment.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies. Conditions: Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer Interventions: Venetoclax Lead Sponsor: AbbVie Planned Enrollment: 165 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (terminated evaluation)
Oncology · 20 Aug 2026
This NICE evaluation was terminated, meaning lisocabtagene maraleucel is not currently recommended for routine NHS use in relapsed or refractory follicular lymphoma—do…
View guideline →
Clinical Brief
‘What terminal cancer has taught me about life’
Oncology · BBC Health · 10 Oct 2026
Personal reflections from a terminal cancer patient offer insights into quality of life and priorities that may inform compassionate end-of-life care discussions…
View brief →
Guideline
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Oncology · 07 Oct 2026
Trastuzumab deruxtecan is recommended by NICE as a treatment option for HER2-low metastatic or unresectable breast cancer, making it suitable for patients…
View guideline →
Clinical Brief
‘I have chronic cancer but I’m not going to die’ – BBC presenter Maryam Moshiri
Oncology · BBC Health · 07 Sep 2026
Polycythaemia vera should be considered in patients with unexplained blood count abnormalities; routine GP testing can identify the condition before symptomatic presentation…
View brief →
Clinical Brief
Cancer patient told she will get drug which could make her life longer
Oncology · BBC Health · 17 Sep 2026
Sacituzumab govitecan is now available on the NHS for patients with incurable (metastatic triple-negative) breast cancer, following a revised cost-effectiveness assessment after…
View brief →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →